The DOI matches its Crossref record; 428 of the 428 references it cites were found in a registry or an index.
Molecular genetics of prostate cancer: new prospects for old challenges
Open accessAbstract
Despite much recent progress, prostate cancer continues to represent a major cause of cancer-related mortality and morbidity in men. Since early studies on the role of the androgen receptor that led to the advent of androgen deprivation therapy in the 1940s, there has long been intensive interest in the basic mechanisms underlying prostate cancer initiation and progression, as well as the potential to target these processes for therapeutic intervention. Here, we present an overview of major themes in prostate cancer research, focusing on current knowledge of principal events in cancer initiation and progression. We discuss recent advances, including new insights into the mechanisms of castration resistance, identification of stem cells and tumor-initiating cells, and development of mouse models for preclinical evaluation of novel therapuetics. Overall, we highlight the tremendous research progress made in recent years, and underscore the challenges that lie ahead.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577 · cited 2×
“…for castration-resistant prostate cancer, as has been shown in genetically engineered mouse models, in gain-of-function studies with orthotopic grafting or tissue recombination models, as well as in human cell lines (Majumder et al. 2003; Uzgare and Isaacs 2004; Gao et al. 2006a; Xin et al. 2006).”
BackgroundRetractedSchlaberg, R., Choe, D. J., Brown, K. R., Thaker, H. M., & Singh, I. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906922106 · Cited by 275
RetractedStem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“Unfortunately, castration-resistant prostate cancer has been essentially untreatable, with the most effective standard chemotherapeutic regimens resulting in a mean increase in survival time of 2 mo (Petrylak et al. 2004; Tannock et al. 2004).”
BackgroundA microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · cited 10×
“Despite the prevalence of these genomic rearrangements , the functional significance of the TMPRSS2-ERG fusion and other ETS rearrangements in prostate cancer is still not fully resolved.”
BackgroundInfluentialIntegrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Cited by
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Punctuated Evolution of Prostate Cancer Genomes
Baca, S. C., Prandi, D., Lawrence, M. S., Mosquera, J. M., Romanel, A., Drier, Y., Park, K., Kitabayashi, N., MacDonald, T. Y., Ghandi, M., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.021 · Cited by 1,320
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., & Mashele, S. (2022) · Molecules · doi:10.3390/molecules27175730 · Cited by 904
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures
Karthaus, W. R., Iaquinta, P. J., Drost, J., Gracanin, A., van Boxtel, R., Wongvipat, J., Dowling, C. M., Gao, D., Begthel, H., Sachs, N., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.017 · Cited by 727
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Lu, X., Horner, J. W., Paul, E., Shang, X., Troncoso, P., Deng, P., Jiang, S., Chang, Q., Spring, D. J., Sharma, P., et al. (2017) · Nature · doi:10.1038/nature21676 · Cited by 547
Ren, S., Peng, Z., Mao, J.-H., Yu, Y., Yin, C., Gao, X., Cui, Z., Zhang, J., Yi, K., Xu, W., et al. (2012) · Cell Research · doi:10.1038/cr.2012.30 · Cited by 362
A Cellular Anatomy of the Normal Adult Human Prostate and Prostatic Urethra
Henry, G. H., Malewska, A., Joseph, D. B., Malladi, V. S., Lee, J., Torrealba, J., Mauck, R. J., Gahan, J. C., Raj, G. V., Roehrborn, C. G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.086 · Cited by 355
Single luminal epithelial progenitors can generate prostate organoids in culture
Chua, C. W., Shibata, M., Lei, M., Toivanen, R., Barlow, L. J., Bergren, S. K., Badani, K. K., McKiernan, J. M., Benson, M. C., Hibshoosh, H., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3047 · Cited by 351
Self-citationA genomic and epigenomic atlas of prostate cancer in Asian populations
Li, J., Xu, C., Lee, H. J., Ren, S., Zi, X., Zhang, Z., Wang, H., Yu, Y., Yang, C., Gao, X., et al. (2020) · Nature · doi:10.1038/s41586-020-2135-x · Cited by 344
Lalonde, E., Ishkanian, A. S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., Dunning, M. J., Halim, S., Lamb, A. D., Moon, N. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71021-6 · Cited by 342
Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing
Fei, T., Chen, Y., Xiao, T., Li, W., Cato, L., Zhang, P., Cotter, M. B., Bowden, M., Lis, R. T., Zhao, S. G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617467114 · Cited by 338
Aytes, A., Mitrofanova, A., Lefebvre, C., Alvarez, M. J., Castillo-Martin, M., Zheng, T., Eastham, J. A., Gopalan, A., Pienta, K. J., Shen, M. M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.017 · Cited by 324
Self-citationSuppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer
Watt, M. J., Clark, A. K., Selth, L. A., Haynes, V. R., Lister, N., Rebello, R., Porter, L. H., Niranjan, B., Whitby, S. T., Lo, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5758 · Cited by 320
Valencia, T., Kim, J. Y., Abu-Baker, S., Moscat-Pardos, J., Ahn, C. S., Reina-Campos, M., Duran, A., Castilla, E. A., Metallo, C. M., Diaz-Meco, M. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.004 · Cited by 304
Qin, J., Liu, X., Laffin, B., Chen, X., Choy, G., Jeter, C. R., Calhoun-Davis, T., Li, H., Palapattu, G. S., Pang, S., et al. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.03.009 · Cited by 317
Wang, Z. A., Mitrofanova, A., Bergren, S. K., Abate-Shen, C., Cardiff, R. D., Califano, A., & Shen, M. M. (2013) · Nature Cell Biology · doi:10.1038/ncb2697 · Cited by 304
Self-citationPSA and beyond: alternative prostate cancer biomarkers
Saini, S. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0268-6 · Cited by 295
Wang, L., Xiong, H., Wu, F., Zhang, Y., Wang, J., Zhao, L., Guo, X., Chang, L.-J., Zhang, Y., You, M. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.053 · Cited by 288
Song, H., Weinstein, H. N. W., Allegakoen, P., Wadsworth, M. H., Xie, J., Yang, H., Castro, E. A., Lu, K. L., Stohr, B. A., Feng, F. Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27322-4 · Cited by 279
Targeting Transcription Factors in Cancer
Bhagwat, A. S., & Vakoc, C. R. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.07.001 · Cited by 276
Tracing the cellular origin of cancer
Blanpain, C. (2013) · Nature Cell Biology · doi:10.1038/ncb2657 · Cited by 276
Shukla, R., Chanda, N., Zambre, A., Upendran, A., Katti, K., Kulkarni, R. R., Nune, S. K., Casteel, S. W., Smith, C. J., Vimal, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121174109 · Cited by 273
Intratumor DNA Methylation Heterogeneity Reflects Clonal Evolution in Aggressive Prostate Cancer
Brocks, D., Assenov, Y., Minner, S., Bogatyrova, O., Simon, R., Koop, C., Oakes, C., Zucknick, M., Lipka, D. B., Weischenfeldt, J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.053 · Cited by 260
Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer
Guo, H., Ahmed, M., Zhang, F., Yao, C. Q., Li, S., Liang, Y., Hua, J., Soares, F., Sun, Y., Langstein, J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3637 · Cited by 226
Multipotent and unipotent progenitors contribute to prostate postnatal development
Ousset, M., Van Keymeulen, A., Bouvencourt, G., Sharma, N., Achouri, Y., Simons, B. D., & Blanpain, C. (2012) · Nature Cell Biology · doi:10.1038/ncb2600 · Cited by 221
Kim, S. M., Nguyen, T. T., Ravi, A., Kubiniok, P., Finicle, B. T., Jayashankar, V., Malacrida, L., Hou, J., Robertson, J., Gao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1215 · Cited by 199
“PTEN is the most frequently deleted tumor suppressor gene in prostate cancer (15, 16); monoallelic PTEN deletion occurs in up to 60% of localized prostate cancers and complete loss of PTEN is commonly associated with increased risk of metastasis and the development of lethal, castration-resistant disease (16, 17).”
BackgroundTimofeeva, O. A., Palechor-Ceron, N., Li, G., Yuan, H., Krawczyk, E., Zhong, X., Liu, G., Upadhyay, G., Dakic, A., Yu, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.13937 · Cited by 65
“Cells of non-malignant and malignant regions of a prostatectomy specimen were grown in keratinocyte serum-free medium (K-SFM) and then transferred to CR conditions to generate immortalized cultures as previously described [8].”
BackgroundMethod
Metadata
- Authors
- Shen, M. M., & Abate-Shen, C.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2010-09-15
- Volume
- 24
- Issue
- 18
- Pages
- 1967-2000
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2148416479
- Cited by
- 946
- References
- 428
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.